EDMONTON, Alberta. Fedora Pharmaceuticals, Inc. announced it has received a non-refundable financial contribution from the National Research Council of Canada’s Industrial Research Assistance Program (NRC-IRAP). The funding, along with technical and business advisory services, is being used to develop a pipeline of antimicrobial product candidates.
Our aim at Fedora is to apply our scientific acumen to the challenge of antimicrobial resistance. Our first effort focused on a family of β-lactamase inhibitors that showed promise against all four classes of β-lactamases and was licensed by Roche in 2015. Building on that success, we have begun development of a pipeline of antimicrobial candidates to address the incredible need that still exists in the treatment of drug-resistant infections.Christopher G. Micetich, Founder & CEO, Fedora Pharmaceuticals
Our efforts align closely with the goals of the Government of Canada, which is committed to addressing AMR through surveillance, stewardship, prevention, and innovation.Christopher G. Micetich, Founder & CEO, Fedora Pharmaceuticals
About Fedora Pharmaceuticals
Fedora Pharmaceuticals Inc. is an innovative biotech founded in 2011 and headquartered in Edmonton, Alberta, Canada. The company is dedicated to discovering and developing novel antimicrobial drugs to tackle antibiotic resistance (AMR). Fedora’s most advanced candidate is nacubactam, a Phase 3-ready β-lactamase inhibitor being advanced with partner Meiji Seika; Fedora holds key US rights to nacubactam. For more information, visit fedorapharma.com.
